Skip to content
Weight Loss Index

Eli Lilly

Eli Lilly and Company is a US pharmaceutical company and one of the central companies in the modern obesity-treatment industry. Its obesity portfolio connects Zepbound, Foundayo, tirzepatide, orforglipron, incretin mechanisms, large clinical programs, manufacturing expansion, regulatory milestones, and direct commercial channels.

The company and pipeline record reviewed here is current to July 23, 2026. Product labels, trial status, manufacturing plans, commercial channels, leadership, pricing, and market access can change; dated primary records should be checked before treating a relationship as current.

Reference record

Section titled “Reference record”
Field Eli Lilly record
Legal name Eli Lilly and Company
Headquarters Indianapolis, Indiana, United States
Company origin Founded by Eli Lilly in Indianapolis in 1876
Chair and CEO David A. Ricks
Listed security New York Stock Exchange under LLY
Core US obesity products Zepbound and Foundayo
Principal obesity-market ingredients Tirzepatide and orforglipron
Selected late-stage obesity asset Retatrutide

Lilly’s 2025 Form 10-K supports the current corporate, product, and financial-reporting context. The company’s leadership record identifies David A. Ricks as chair and chief executive officer.

Why Eli Lilly matters in obesity treatment

Section titled “Why Eli Lilly matters in obesity treatment”

Lilly links approved and investigational products across three incretin strategies. Tirzepatide activates GIP and GLP-1 receptors and is marketed for obesity in the United States as Zepbound. Orforglipron is an oral small-molecule GLP-1 receptor agonist marketed as Foundayo. Retatrutide is an investigational GIP, GLP-1, and glucagon receptor agonist in phase 3 development.

The portfolio also shows why company, ingredient, product, indication, and development-program records must remain separate. Zepbound and Mounjaro contain the same active ingredient but have different product and label records. Foundayo is a separate molecule and product, while retatrutide remains investigational as of the review date.

Approved and adjacent product portfolio

Section titled “Approved and adjacent product portfolio”
Product Active ingredient Company and market relationship Status boundary
Zepbound Tirzepatide Lilly’s injectable US obesity product, with adult weight-reduction and obstructive-sleep-apnea indications Separate product and label from Mounjaro
Foundayo Orforglipron Lilly’s once-daily oral GLP-1 obesity product approved by FDA on April 1, 2026 Approval applies to the product, population, route, indication, and jurisdiction in the label
Mounjaro Tirzepatide Diabetes-market product sharing the tirzepatide ingredient and supply platform A shared ingredient does not transfer Zepbound’s obesity or obstructive-sleep-apnea indications

The current DailyMed Zepbound label, current DailyMed Mounjaro label, and FDA Foundayo approval record support these product distinctions.

Obesity and cardiometabolic pipeline

Section titled “Obesity and cardiometabolic pipeline”

Pipeline status is dated and does not establish approval, launch, availability, or coverage.

Asset or program Mechanism or composition Status as reviewed Relationship to the company portfolio
Retatrutide GIP, GLP-1, and glucagon receptor agonist Investigational phase 3 asset; Lilly reported positive TRIUMPH-1 topline results in May 2026 Extends Lilly’s portfolio from dual- to triple-receptor agonism
SURMOUNT-MMO Tirzepatide morbidity and mortality outcomes study Ongoing phase 3 study with a registry update posted in January 2026 Tests tirzepatide in a broader obesity-outcomes context beyond existing Zepbound indications
Pediatric tirzepatide studies Tirzepatide obesity-development studies in adolescents Clinical development remains separate from the adult US Zepbound label A trial population does not establish pediatric approval

Lilly’s May 2026 TRIUMPH-1 announcement, the TRIUMPH-1 registry record, SURMOUNT-MMO registry record, and SURMOUNT-ADOLESCENTS-2 registry record provide dated status context. Company-reported topline results require trial design, analysis, publication, and regulatory context before comparative reuse.

Clinical-program relationships

Section titled “Clinical-program relationships”
Program Company relationship Connected record
SURMOUNT Lilly-sponsored tirzepatide obesity and weight-management program Tirzepatide, Zepbound, obesity studies, obstructive sleep apnea, and outcomes research
SURPASS Lilly-sponsored tirzepatide type 2 diabetes program Mounjaro and the diabetes-development history of the shared ingredient
ATTAIN Lilly-sponsored orforglipron phase 3 program Foundayo’s oral GLP-1 development and FDA approval record
TRIUMPH Lilly-sponsored retatrutide phase 3 program Investigational triple-receptor obesity and cardiometabolic development

Clinical-program records should preserve individual trial identifiers, populations, comparators, durations, endpoints, status dates, and sources. A program name is not a substitute for a trial record, and results from one study should not be generalized across a whole program.

Regulatory relationships

Section titled “Regulatory relationships”

Lilly’s company record connects to product-specific regulatory events rather than one company-wide approval status.

Date Event Company significance
May 13, 2022 FDA approved Mounjaro for glycemic control in adults with type 2 diabetes Established the first US tirzepatide product record
November 8, 2023 FDA approved Zepbound for long-term weight reduction and maintenance in a defined adult population Established Lilly’s first US tirzepatide obesity-product record
December 20, 2024 FDA added Zepbound’s moderate-to-severe obstructive-sleep-apnea indication for adults with obesity Connected the product to an obesity-related sleep-medicine indication
2024–2026 FDA cleared additional Zepbound vial, multi-dose, and KwikPen presentations through supplemental records Expanded the product-presentation and commercial-channel landscape without creating a new active ingredient
April 1, 2026 FDA approved Foundayo for long-term weight reduction and maintenance in a defined adult population Added a separate oral GLP-1 product to Lilly’s obesity portfolio

The FDA Mounjaro approval snapshot, FDA Zepbound weight-management approval notice, FDA Zepbound obstructive-sleep-apnea notice, and FDA Foundayo approval letter support these dated milestones.

Manufacturing and supply network

Section titled “Manufacturing and supply network”

Lilly’s obesity-product supply depends on active-ingredient production, formulation, filling, devices, packaging, and distribution across a broader manufacturing network. A company investment announcement does not establish that a planned facility is already producing a particular product.

In May 2026, Lilly said its planned Lebanon, Indiana, active-pharmaceutical-ingredient site would support Zepbound and Mounjaro and was expected to open in 2027. The same announcement described additional planned capacity for Foundayo and investigational retatrutide. This is future-capacity context, not evidence about the facility that produced any currently dispensed unit.

The May 2026 Indiana manufacturing announcement and the manufacturing discussion in Lilly’s 2025 Form 10-K document the dated expansion record. Physical manufacturing, current output, local inventory, and supply continuity require more specific sources.

Commercial and access channels

Section titled “Commercial and access channels”

LillyDirect is part of Lilly’s US commercial-access strategy, but the platform should not be confused with insurance coverage, universal eligibility, stable price, or local availability.

Lilly began offering Zepbound single-dose vials through a LillyDirect self-pay channel in August 2024 and later expanded the available vial strengths. The August 2024 channel announcement provides a dated record of that relationship.

Commercial terms, presentation availability, pharmacy relationships, payer coverage, reimbursement, and patient eligibility can change. Current channel details should therefore be treated as market-access records with a date rather than permanent product attributes.

Company-history context

Section titled “Company-history context”

Eli Lilly founded the company in Indianapolis in 1876. Its later position in obesity treatment grew from a much broader pharmaceutical history that includes diabetes medicines, peptide manufacturing, injection devices, and cardiometabolic research.

This history helps explain the infrastructure behind tirzepatide and Lilly’s later obesity portfolio. It does not imply that the current products, mechanisms, business units, or manufacturing sites existed throughout the company’s history.

Interpretation boundaries

Section titled “Interpretation boundaries”
  • Lilly’s connection to a product does not by itself identify the physical manufacturer, packager, distributor, approval holder, or commercial partner in every jurisdiction.
  • Zepbound and Mounjaro share tirzepatide but remain different products with different label records.
  • Foundayo is a separate active ingredient, product, route, and approval record from Zepbound.
  • Retatrutide is investigational as of July 23, 2026; phase 3 results do not establish approval or commercial availability.
  • A trial result should retain population, comparator, duration, endpoint, analysis, and source context.
  • FDA approval does not establish launch timing, insurance coverage, reimbursement, local inventory, price, affordability, or clinical suitability.
  • Manufacturing investments and planned facilities do not identify the source of a specific marketed unit or guarantee future supply.
  • Corporate and financial records are included for industry identity and relationship mapping, not investment advice.
Section titled “Related records”